New drug KT-579 enters first human safety tests
NCT ID NCT07412288
First seen Feb 18, 2026 · Last updated May 01, 2026 · Updated 12 times
Summary
This early-stage study tests the safety of a new oral drug called KT-579 for the first time in people. About 96 healthy adults will receive either the drug or a placebo to see how the body processes it and if any side effects occur. The goal is to gather initial safety data, not to treat any disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Celerion
RECRUITINGLincoln, Nebraska, 68502, United States
Conditions
Explore the condition pages connected to this study.